Preventing low platelets during T-DM1 for HER2-positive breast cancer
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether a drug called Herombopag can prevent low blood platelets, a common side effect of the breast cancer treatment T-DM1. If you are about to start T-DM1, this trial may help maintain healthy platelet levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older.
- You have been diagnosed with HER2-positive breast cancer.
- Your doctor has decided to treat you with the drug T-DM1.
- You are physically able to care for yourself (ECOG score of 0-2).
- You have no other blood diseases that cause low platelets, and no recent history of bleeding or clotting problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibody-drug conjugate (DP303c) against an existing one, T-DM1, in people with HER2-positive advanced breast cancer who have already been treated with trastuzumab and a taxane. The goal is to see if the new drug works better or has fewer side effects.
This trial tests whether a new drug called BL-M07D1 works better than an existing drug, T-DM1, for people with HER2-positive breast cancer who still have cancer cells after initial treatment (neoadjuvant therapy). The goal is to prevent the cancer from coming back.
This trial tests if herombopag can help raise platelet counts in breast cancer patients who have low platelets caused by the drug T-DM1 after prior anti-HER2 therapy. If it works, it may allow you to continue T-DM1 without delays or dose reductions.
This trial studies a pill called herombopag to see if it can prevent low blood platelets caused by chemotherapy (and sometimes radiation) in people with cervical cancer. Low platelets increase the risk of bleeding, and this drug may help keep platelet levels safer so you can continue your cancer treatment.
This study tests a drug called hetrombopag to see if it can help prevent a drop in blood platelets (cells that help blood clot) caused by antibody-drug conjugate (ADC) cancer therapy. It may help patients who have already had low platelets from their treatment or are about to start an ADC regimen.
This study tests an oral medication, hetrombopag, to see if it can safely raise platelet counts in people with gynecologic cancers whose platelets drop too low from chemotherapy or other cancer treatments. It may help them continue their cancer therapy without delays or bleeding risks.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.